Found 126 articles for: "COVID"
Tocilizumab Treatment in COVID-19 Patients: Comparing Cutaneous Disease and Adverse Drug Effects
December 2023 | Volume 22 | Issue 12 | Editorials | e42 | Copyright © December 2023
Actemra (tocilizumab) received emergency use authorization for the treatment of coronavirus disease 2019 (COVID-19) in June 2021. Literature has linked numerous cutaneous adverse effects to tocil...
Read MoreTelemedicine Versus Teledermatology Usage and Perception Among US-Based Physicians: A Survey Study
November 2023 | Volume 22 | Issue 11 | Features | e4 | Copyright © November 2023
The COVID-19 pandemic has sparked an increase in focus and use of telemedicine in several patient care settings. This survey study was distributed to actively practicing US-based physicians and e...
Read MorePerceived Barriers to Career Advancement: Medical Students and Resident Physicians
November 2023 | Volume 22 | Issue 11 | Features | e17 | Copyright © November 2023
Background: The path to becoming a physician is challenging, with various barriers influencing medical student and resident physician residency and fellowship training career dec...
Read MoreIndividual Article: A Novel 3-Step Over-the-Counter Eczema Regimen Improves Eczema Severity, Itch, and Life Quality: Randomized Study
October 2023 | Volume 22 | Issue 10 | Supplement Individual Articles | SF388641s21 | Copyright © October 2023
Background: Eczema, or atopic dermatitis (AD), is a chronic relapsing skin disease associated with unpredictable flares of erythema, rash, and pruritus. AD arises from a combinat...
Read MoreIndividual Article: Brodalumab Is an Efficacious, Safe, and Cost-Effective IL-17 Receptor Blocker for the Treatment of Moderate-to-Severe Plaque Psoriasis: 2023 Update
October 2023 | Volume 22 | Issue 10 | Supplement Individual Articles | SF378632s5 | Copyright © October 2023
Psoriasis remains a highly prevalent condition in the United States and worldwide. Preclinical research has been triumphant in elucidating the critical immunological pathways involved in psoriasi...
Read MoreParticipant Satisfaction of a Community-based Telehealth Clinic for Atopic Dermatitis
October 2023 | Volume 22 | Issue 10 | Editorials | 1066 | Copyright © October 2023
Atopic dermatitis (AD), a chronic, relapsing inflammatory disease that affects more than 30 million children and adults in the US, disproportionally impacts African American (AA) and Hispanic children...
Read MoreComparing the Efficacy for Pulse Versus Continuous Dose Terbinafine Therapy in Patients With Onychomycosis
October 2023 | Volume 22 | Issue 10 | Original Article | 1017 | Copyright © October 2023
Recently, treatment outcomes in patients with toenail onychomycosis have improved considerably due to more effective oral antifungal medications such as terbinafine and itraconazole. These medica...
Read MoreA Randomized Control Trial Comparing the Efficacy of Platelet-Rich Plasma and 5% Topical Minoxidil for the Treatment of Androgenetic Alopecia
September 2023 | Volume 22 | Issue 9 | Original Article | 905 | Copyright © September 2023
Androgenetic alopecia (AGA) is the most common cause of hair loss in men and has limited treatment options. Minoxidil is a common therapeutic option for AGA patients because of its availability. Plate...
Read MoreClinical Trial of Alpha and Beta Defensin Skin Care Regimen for Improvement of Periocular Wrinkles
September 2023 | Volume 22 | Issue 9 | Original Article | 874 | Copyright © September 2023
Background: Defensins recruit leucine-rich repeat-containing G protein-coupled receptor 6 positive (Lgr6+) stem cells which ultimately regenerate new basal stem cells, healthy ke...
Read MoreOff-Label Use of Baricitinib in Dermatology
August 2023 | Volume 22 | Issue 8 | Original Article | 795 | Copyright © August 2023
The current US Food and Drug Administration (FDA) indications for baricitinib include alopecia areata, rheumatoid arthritis, and COVID-19. However, increasing evidence indicates that baricitinib ...
Read MoreTildrakizumab in Combination With Topical Halcinonide 0.1% Ointment for Treating Moderate to Severe Plaque Psoriasis
August 2023 | Volume 22 | Issue 8 | Original Article | 766 | Copyright © August 2023
Background: This prospective, open-label study evaluated the effectiveness and safety of tildrakizumab plus topical halcinonide ointment in psoriasis patients.Read More Antimalarials are not Effective as Pre-Exposure Prophylaxis for COVID-19: A Retrospective Matched Control Study
August 2023 | Volume 22 | Issue 8 | Editorials | 840 | Copyright © August 2023
The early phase of the COVID-19 pandemic prompted a repurposing of antiviral and immunomodulatory drugs as investigational therapeutics, including hydroxychloroquine and chloroquine. While antima...
Read MoreReal-World Effectiveness and Safety of Tildrakizumab in Patients With Moderate-to-Severe Psoriasis: Week 28 Interim Analysis of a Phase 4 Study
August 2023 | Volume 22 | Issue 8 | Original Article | 754 | Copyright © August 2023
Background: Tildrakizumab is an anti–interleukin-23 p19 monoclonal antibody approved for the treatment of adults with moderate-to-severe plaque psoriasis. This analysis eva...
Read MoreCeramide-Containing Adjunctive Skin Care for Skin Barrier Restoration During Acne Vulgaris Treatment
June 2023 | Volume 22 | Issue 6 | Original Article | 554 | Copyright © June 2023
Barrier damage caused by facial acne vulgaris can be magnified by topical medication, such as adapalene (0.3%) and benzoyl peroxide (2.5%)(A/BPO), which utilizes a retinoid to normalize follicula...
Read MoreAssessment and Evaluation of Online Content Available on Micrographic Surgery and Dermatologic Oncology Fellowship Websites
May 2023 | Volume 22 | Issue 5 | Features | 521 | Copyright © May 2023
Optimizing Melasma Management With Topical Tranexamic Acid: An Expert Consensus
April 2023 | Volume 22 | Issue 4 | Original Article | 386 | Copyright © April 2023
Because of its complex pathogenesis, chronicity, and high rates of recurrence, melasma is regarded as a challenging skin disorder. Topical treatments are often offered as first-line therapy. Howe...
Read MoreBrodalumab: 4-Year US Pharmacovigilance Report
April 2023 | Volume 22 | Issue 4 | Features | 419 | Copyright © April 2023
Brodalumab is an interleukin-17 receptor A antagonist approved for the treatment of moderate-to-severe psoriasis in adults without response or with loss of response to other systemic therapies. B...
Read MoreReversal of Stress-Associated Alopecia
March 2023 | Volume 22 | Issue 3 | Case Reports | 300 | Copyright © March 2023
Novel coronavirus SARS-CoV-2, designated as COVID-19 by the World Health Organization (WHO) on February 11, 2020, is one of the highly pathogenic β-coronaviruses that infects humans.1 ...
Read MoreSuccessful Management of Erythema Dyschromicum Perstans Following Topical Ruxolitinib Therapy
March 2023 | Volume 22 | Issue 3 | Case Reports | 297 | Copyright © March 2023
Erythema dyschromicum perstans (EDP) is a rare cutaneous disorder in which patients develop gray or blue-brown macules or patches on their bodies.1 This condition does not appear to have a ...
Read MoreCharacteristic Distinctions Between Pre-/Post-COVID-19 Teledermatology Adoptees: A Cross-Sectional United States-based Analysis and the Implications for Dermatologic Healthcare Equity
January 2023 | Volume 22 | Issue 1 | Editorials | 101 | Copyright © January 2023
Background: Studies suggest potential heterogeneity in telemedicine adoption with potential to exacerbate healthcare access inequity.
Methods: A pre-validated s...
Read MoreMedia and other results for: "COVID"